PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Up 7.9% in April-June 2015: IMS
August 6, 2015
- 14-Day Limit on Prescriptions Considered Unnecessary from a Safety Standpoint in the US and Europe: Pfizer Pres. Umeda
August 6, 2015
- 80% Generic Target “Completely Unexpected,” and Makes Stable Growth in Japan Market Difficult: Pfizer Pres.
August 6, 2015
- AZ Japan Sales Up 2% to US$977 Million in 1st Half of 2015
August 6, 2015
- Astellas Transfers Muscle Relaxant Suxamethonium to Maruishi on Oct. 1
August 6, 2015
- Naldemedine Demonstrates Favorable Results in 3 PIII Efficacy Studies for Opioid-Induced Constipation: Shionogi
August 5, 2015
- Santen Transfers Anti-Rheumatic Business to Ayumi Pharmaceutical
August 5, 2015
- GSK Suspends Shipment of Anti-MRSA Agent Bactroban
August 5, 2015
- Daiichi Sankyo to Submit 4 Products for Approval in Japan and Overseas through FY2018
August 4, 2015
- Edoxaban Doing Well in Japan, but Off to a Rocky Start in US: Daiichi Sankyo
August 4, 2015
- Astellas Not Keen on Biosimilars: CFO Masuda
August 4, 2015
- Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI
August 4, 2015
- Fuji Pharma to Obtain Marketing Rights for 3 Imaging Agents from Guerbet Japan
August 4, 2015
- Kyowa Kirin to Draw Up 5-Year Midterm Plan Focusing on Development of Global Products: President Hanai
August 4, 2015
- MTPC Files Edaravone for Amyotrophic Lateral Sclerosis in South Korea
August 4, 2015
- Kyowa Kirin’s Pharma Business Sales Up 13% Driven by New Products, Overseas Business in 1st Half of FY2015
August 3, 2015
- JCR Files for Growject Liquid Formulation
August 3, 2015
- Ono Files Opdivo for Use in Chemotherapy-Naïve Patients
August 3, 2015
- Post-Marketing Study Shows No Causal Relationship of Actos with Bladder Cancer: Takeda
August 3, 2015
- Novartis Files NDA for Acromegaly Treatment Pasireotide in Japan
August 3, 2015
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…